Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Corporation PLC Shares Were Hammered

By Sean Williams – Jan 21, 2014 at 1:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Adding insult to injury, the Food and Drug Administration sends Amarin away empty-handed once again!

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Amarin (AMRN), a biopharmaceutical company focused on creating therapies to treat cardiovascular diseases, tumbled as much as 26% after the Food and Drug Administration issued a response to its request to have its special protocol assessment (SPA) reinstated for Vascepa in the ANCHOR trial.

So what: According to Amarin's press release, the Division of Metabolism and Endocrinology Products (DMEP) has denied Amarin's request to reinstate the SPA in the ANCHOR trial, ending any hope that there would be a quicker channel to expanding Vascepa's approval beyond the current indication of treating patients with extremely high triglyceride levels (at least 500 mg/DL or greater) to a larger chunk of the population that falls into the high triglyceride range (200 mg/DL through 499 mg/DL). Amarin plans to appeal the DMEP's decision.

Now what: With the FDA essentially putting its foot down for a second time, Amarin is going to have no choice but to complete its REDUCE-IT cardiovascular outcomes study if it has any hope of expanding Vascepa's indicated uses. Unfortunately, this trial is going to take years and millions of dollars to complete, so it will be a while before Amarin has any chance of realizing a sizable monetary impact from Vascepa. In the meantime, Amarin has let go of a good chunk of its workforce and may need to rein in costs even further if it hopes to complete the REDUCE-IT study. All things considered, I'd suggest keeping a safe distance from Amarin moving forward.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Stock Quote
$1.17 (%)

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.